Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate- specific antigen working group Academic Article uri icon

Overview

MeSH Major

  • Clinical Trials, Phase II as Topic
  • Consensus Development Conferences, NIH as Topic
  • Patient Selection
  • Prostate-Specific Antigen
  • Prostatic Neoplasms

abstract

  • Through this consensus conference, we believe we have developed practical guidelines for using PSA as a measurement of outcome. Furthermore, the use of common standards is important as we determine which agents should progress to randomized trials which will use survival as an end point.

publication date

  • November 1999

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10550143

Additional Document Info

start page

  • 3461

end page

  • 7

volume

  • 17

number

  • 11